Share Name Share Symbol Market Type Share ISIN Share Description
Evgen Pharma Plc LSE:EVG London Ordinary Share GB00BSVYN304 ORD 0.25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 6.50 6.20 6.80 6.50 6.50 6.50 0.00 08:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -3.1 -2.7 - 9

Evgen Pharma Share Discussion Threads

Showing 1701 to 1724 of 1875 messages
Chat Pages: 75  74  73  72  71  70  69  68  67  66  65  64  Older
DateSubjectAuthorDiscuss
31/10/2019
07:44
Nobby, no have very little direct knowledge. Been on my radar and near a read-out, so just a small punt.
waterloo01
30/10/2019
19:26
>> waterloo Interesting to see you have bought in here. I have a small position but am reticent to buy any more. I don't really have any specific reason like my scientific analysis over at IMM but I guess it's just gut feeling. Are you confident of a good result? I can see much better short term opportunities elsewhere such as STX and SBTX.
nobbygnome
30/10/2019
19:14
Took a 1st small position today. Some very large trades (not mine). Always value diamondstar1 and Timbo's input. Knowledgeable chaps.
waterloo01
30/10/2019
19:12
Thanks diamondstar.
lovewinshatelosses
30/10/2019
18:35
Timbo - the 40% figure I quoted comes from Medscape, and is based on hospitalised SAH patients. The mortality would be even higher considering the 20% who pass away before reaching hospital. Shows you how devastating this disease is. LWHL - the trial would be of similar duration for the patient. However, the patient numbers would increase. For the pivotal Ph3 Nimodipine trial, N = 554. This would mean that you will need more sites and countries running the study. How fast the Ph3 study is run will depend on how much money you have, as you could set up more sites/countries. Obviously, a licensing deal with a Pharma partner would be ideal.
diamondstar1
30/10/2019
17:38
Does anyone know approximately how long phase 3 would likely take, in the event all goes well here and such things become applicable - or it that a piece of string question?
lovewinshatelosses
30/10/2019
16:54
The last few posts remind me of something SF mentioned at one of the investor meetings a few months ago i.e. don't confuse the overall mortality (30-40%) for SAH with mortality in hospitalised patients (which is a significantly lower figure), because around 20% of patients with SAH never make it (alive) to hospital for treatment.
timbo003
30/10/2019
16:15
Good post Nelson. Evaluable subjects - this is also known from a statistical perspective as the Per Protocol Set (PPS). These are patients who have 1)Completed a minimum predefined observational period 2)Have measurements for the Primary Outcome 3)Have not met criteria for Major Protocol Violations. Usually, you get a few patients who do not make it to the PPS. Hence, this could explain the potential discrepancy between 9.5% and 16%. Hence, mortality could be closer to 10% (as per figure at 71% enrollment) or slightly higher, and you may also have a few % of patients excluded from the final analysis (example, due to major protocol violations or incomplete data).
diamondstar1
30/10/2019
15:46
That's interesting figures, I've also read 107 patients recruited with 89 being evaluable. Which I took as 16% mortality rate.
90005nelson
30/10/2019
14:55
That's great information you've posted L0ngterm! Overall mortality with 71% patients - at 9.5% is VERY low, compared to overall mortality rates for SAH in general, near 30-40%. Hence, it looks to me like more healthy patients were enrolled (i.e. patients with reduced conscious state/coma or severe hemiplegia excluded). This is promising - to maximise potential effects on Rankin Score, which is a Secondary Outcome Measure.
diamondstar1
30/10/2019
14:44
Some figures from March 2019 on the trial. Link below. "64 (71% of the target) patients have been enrolled. 35 patients have completed the study. Statistical analysis of the TCD data will be performed at the end of the trial. The mortality is at 9.5% (6). DSMB have met twice since the start of the trial and there have been no safety concerns. Conclusions The trial is recruiting on the planned trajectory and at this rate we are projected to complete the trial by the end of the year."https://www.google.co.uk/amp/s/www.researchgate.net/publication/331102933_WM1-2_SFX-01_after_subarachnoid_haemorrhage_protocol_of_a_multi-centre_phase_II_double-blinded_randomised_controlled_trial/amp
l0ngterm
30/10/2019
14:02
I anticipate that the study results will be out over the next 2 weeks. Here are my predictions of the study results, for the 3 Primary Outcome Measures:- 1) Adverse Event Evaluation (safety of SFX-01 vs. placebo) - this is really a no brainer for me - because previous public disclosures by Evgen on the DSMB (Data Safety Monitoring Board ) findings have already indicated that the drug is very safe and well tolerated vs. placebo. CONCLUSION - SFX-01 very safe in SAH patients 2) Maximum CSF concentration - previous animal studies have shown that SFX-01 crosses the blood brain barrier (BBB). SFX-01 being a small molecule, should have no problems crossing BBB. CONCLUSION - DRUG WILL BE FOUND IN CSF, PASS! 3) No of patients with reductions in middle cerebral artery (MCA) peak flow velocity. Previous animal studies have shown that SFX-01 alleviates cerebral artery vasospasm secondary to oxyhaemoglobin formation. Note - only 30-40% of patients will have significant vasospasm after SAH - but I would expect SFX-01 to have positive effects in these patients. CONCLUSION - LIKELY SOME POSITIVE EFFECT WILL BE SEEN, MAINLY IN SUBSET OF PATIENTS WITH CEREBRAL ARTERY VASOSPASM. The results will be very very interesting if they find that SFX-01 reduces mortality in SAH patients vs. placebo. Note that this reduction in mortality has been seen in several animal studies with NRF2 activators:- ref: Neuroprotective Role of the Nrf2 Pathway in Subarachnoid Haemorrhage and Its Therapeutic Potential (Zolnourian et al, 2019). A reduction in mortality, if seen, could impact the Secondary Outcome Measure of the study - namely the Rankin Score - if more patients actually survive on SFX-01 vs. placebo. Paradoxically, those who survive on SFX-01 could be left with more significant neurological deficit. Hence, SFX-01 may have the potential to help SAH patients survive, who might have otherwise perished if they did not receive SFX-01. Will be interesting to see overall effect on Rankin Score. Interesting times ahead - I'm looking forward to the results! Primary Outcome Measures - likely to be very good, but secondary outcome measures may be interesting, especially if SFX-01 impacts mortality. Overall, I'd expect this study to give the green light for the next phase i.e. Ph3.
diamondstar1
25/10/2019
17:25
Results anytime from next week.
90005nelson
21/10/2019
12:56
thanks pennyfalls.gl
purple11
20/10/2019
15:08
Don't take it as gospel , purple11, but I think approx Mid-Q4 has been talked about. I would think anytime between now and mid - to end November
pennyfalls
19/10/2019
09:39
when do ppl think these results will be released?are we looking at nov/dec ?
purple11
16/10/2019
20:44
Hi PF. I suspect your estimated range is far more likely to be closer to the mark than mine. While I agree from a long term perspective it probably does not matter anyway, the low base does act as a drag on proceedings. This is part and parcel of small pharma stocks I guess - the fairly vague window for results/material news can lead to impatient PI's speculating all over the place!
lovewinshatelosses
16/10/2019
19:18
Thanks for continuing to follow me around ‘tick-downR17; troll.. Although I value your continued support greatly, I do know a few pretty good psychotherapists if you fancy getting out more.. Hi LWHL :o) Ref today’s price action, looks like the average trading volume is set to increase up to news, but reckon MMs will be taking it down and bit then levelling it off again, just to make a market. I don’t expect to see a rise to 18p unless there’s a (good) leak, and think it’ll stay circa 13.5-15p.. Not really relevant tbh as it’s all on the RNS, although I suppose I;d rather see a higher ‘base’ level to move from.
pennyfalls
16/10/2019
13:12
I am certainly not sure PF, nor looking to do anything further with this share until results at the earliest; it was only to probably demonstrate my total inability to call these things accurately in the short term! I am impressed by those commentators on these boards who do seem to call it very accurately on a regular basis, but only as a matter of interest, rather than with a view to try and trade on it. Only for a bit of fun.
lovewinshatelosses
16/10/2019
12:33
LWHL...I wouldn’t be so sure on it continuing upwards pre-news..
pennyfalls
16/10/2019
11:19
Thinking out loud, I wonder what the share price will reach at the last minute before news? Will we touch a new year high? I am going to plump for 18p (based on nothing at all). After the results, whatever they are, I have no clue whatsoever but I do enjoy the anticipation!
lovewinshatelosses
16/10/2019
09:33
The results will be a great trading opportunity but it's what happens after the results that will take this share stratospheric.
90005nelson
16/10/2019
08:54
Morning.. I thought some of those might have bene buys yesterday and inflection point hit. Looks like 13.5 was the technical support bounce. Doubt we'll see that again before news. Good luck all..investors and traders both
pennyfalls
16/10/2019
08:08
im one of "those" traders whos back in this morning.im in for the news.gla
purple11
Chat Pages: 75  74  73  72  71  70  69  68  67  66  65  64  Older
Your Recent History
LSE
EVG
Evgen Phar..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200127 08:29:49